Cartesian Therapeutics, Inc. Common Stock
RNAC Real Time Price USDRecent trades of RNAC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RNAC's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anti-bcma chimeric antigen receptors Jun. 04, 2024
-
Patent Title: Anti-bcma chimeric antigen receptors Jan. 11, 2022
-
Patent Title: Anti-bcma chimeric antigen receptors Mar. 02, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RNAC in WallStreetBets Daily Discussion
Recent insights relating to RNAC
Recent picks made for RNAC stock on CNBC
ETFs with the largest estimated holdings in RNAC
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RNAC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.